ONCT vs. UBX, ITRM, ACST, FBRX, LSTA, BIOR, JAN, NNVC, RNXT, and ENLV
Should you be buying Oncternal Therapeutics stock or one of its competitors? The main competitors of Oncternal Therapeutics include Unity Biotechnology (UBX), Iterum Therapeutics (ITRM), Acasti Pharma (ACST), Forte Biosciences (FBRX), Lisata Therapeutics (LSTA), Biora Therapeutics (BIOR), JanOne (JAN), NanoViricides (NNVC), RenovoRx (RNXT), and Enlivex Therapeutics (ENLV). These companies are all part of the "pharmaceutical preparations" industry.
Unity Biotechnology (NASDAQ:UBX) and Oncternal Therapeutics (NASDAQ:ONCT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, community ranking, valuation, analyst recommendations, institutional ownership, earnings and risk.
29.5% of Unity Biotechnology shares are held by institutional investors. Comparatively, 16.1% of Oncternal Therapeutics shares are held by institutional investors. 4.9% of Unity Biotechnology shares are held by company insiders. Comparatively, 8.0% of Oncternal Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Oncternal Therapeutics had 11 more articles in the media than Unity Biotechnology. MarketBeat recorded 17 mentions for Oncternal Therapeutics and 6 mentions for Unity Biotechnology. Oncternal Therapeutics' average media sentiment score of 1.06 beat Unity Biotechnology's score of 0.43 indicating that Unity Biotechnology is being referred to more favorably in the media.
Unity Biotechnology has a net margin of 0.00% compared to Unity Biotechnology's net margin of -3,160.73%. Oncternal Therapeutics' return on equity of -95.06% beat Unity Biotechnology's return on equity.
Oncternal Therapeutics has higher revenue and earnings than Unity Biotechnology. Oncternal Therapeutics is trading at a lower price-to-earnings ratio than Unity Biotechnology, indicating that it is currently the more affordable of the two stocks.
Unity Biotechnology has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, Oncternal Therapeutics has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500.
Unity Biotechnology received 144 more outperform votes than Oncternal Therapeutics when rated by MarketBeat users. Likewise, 66.28% of users gave Unity Biotechnology an outperform vote while only 31.87% of users gave Oncternal Therapeutics an outperform vote.
Unity Biotechnology presently has a consensus target price of $6.00, suggesting a potential upside of 294.76%. Oncternal Therapeutics has a consensus target price of $28.33, suggesting a potential upside of 227.17%. Given Oncternal Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Unity Biotechnology is more favorable than Oncternal Therapeutics.
Summary
Unity Biotechnology beats Oncternal Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Oncternal Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ONCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oncternal Therapeutics Competitors List
Related Companies and Tools
